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Introduction
Protein cages, such as ferritins, small heat shock proteins, and viral capsids are prom-
ising nanoplatform candidates for efficient delivery systems because they have uni-
form size, structure, high biocompatibility and biodegradability [1-6]. The protein cag-
es are spontaneously self-assembled from multiple copies of one or a few types of pro-
tein subunits in a precisely controlled manner [1-6]. Also, they can be genetically and 
chemically manipulated to have desired functionality by rational design on the basis 
of atomic resolution structural information.
 The lumazine synthase, isolated from hyperthermophile Aquifex aeolicus (AaLS), 
consists of 60 identical subunits forming an icosahedral capsid architecture (T=1 state) 
with a 15.4 nm exterior and a 9 nm interior diameters, respectively [7]. The AaLS origi-
nally catalyzes the penultimate step in riboflavin biosynthesis within the cell. Outside 
of the cell, its hollow sphere architecture has been used as a template for encapsula-
tion of cargo proteins such as green fluorescent proteins [8], human immunodeficien-
cy virus proteases [9], crystallization of inorganic nanoparticles such as iron oxide [10], 
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Purpose: Protein cages are promising nanoplatform candidates for efficient delivery systems 
due to their homogenous size and structure with high biocompatibility and biodegradability. In 
this study, we investigate the potential of lumazine synthase protein cage as an antigen delivery 
system to dendritic cells (DCs), which induce antigen-specific T cell proliferation. 
Materials and Methods: Ovalbumin (OVA) peptides OT-1 (SIINFEKL) and OT-2 (ISQAVHAA-
HAEINEAGR) were genetically inserted to lumazine synthase and each protein cage was over-
expressed in Escherichia coli as a soluble protein. The efficiency of antigen delivery and the 
resulting antigen-specific T cell proliferation by DCs was examined in vitro as well as in vivo. 
Results: We successfully generated and characterized OVA peptides carrying lumazine syn-
thase protein cages. The OT-1 and OT-2 peptides carried by lumazine synthases were efficient-
ly delivered and processed by DCs in vitro as well as in vivo, and induced proliferation of OT-
1-specific CD8+ T cells and OT-2-specific CD4+ T cells. 
Conclusion: Our data demonstrate the potential of lumazine synthase protein cage being used 
as a novel antigen delivery system for DC-based vaccine development in future clinical appli-
cations. 
Keywords: Dendritic cells, Protein cage, Antigen presentation, Vaccines, Nanoparticles
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and fabrication of uniform layer-by-layer assemblies using 
non-covalent interaction between surface displayed hexa-
hisitidine and Ni-NTA of the AaLS [11].
 Dendritic cells (DCs) are the most potent professional an-
tigen-presenting cells and key regulator of antigen-specific 
immune responses [12]. Immature DCs continously uptake 
and process antigens. Upon danger signal, the antigen-load-
ed DCs migrate into draining lymph nodes where DCs pres-
ent antigens to naïve T cells leading to their proliferation and 
differentiation into effector cells; CD8+ cytotoxic T cells to kill 
infected target cells or CD4+ helper T cells to secrete cytokines 
and facilitate diverse forms of cellular and humoral immuni-
ty. Therefore, based on such seminal roles of DCs in the im-
mune system, DC-based vaccine development has been a 
promising approach to direct antigen-specific adaptive im-
munity [13].
 Efficient antigen delivery to DCs is the first step for DC-based 
vaccine development and simple and controllable antigen 
delivery system is required. Up to date, nano-sized materials, 
including polymers, inorganic nanoparticles, liposomes, and/ 
or virus-like particle (VLP), have been extensively used as an-
tigen delivery nanoplatforms for studying antigen-specific 
immune responses and further applied them to follow-up 
vaccine development. However, there is a limited amount of 
study utilizing protein cage nanoparticles to deliver antigens 
to DCs for immunization and vaccination. In our previous 
study, we utilized ferritin protein cage nanoparticles as versa-
tile antigen delivery nanoplatforms for DC-based vaccine de-
velopment and demonstrated DC-mediated antigen specific 
CD4+ and CD8+ T cell immune responses [14]. In the current 
study, we introduce lumazine synthase protein cage nano-
particles (AaLS) for carrying antigenic peptides to DCs and 
investigate DC-mediated antigen-specific T cell proliferation. 
Our data demonstrate the potential of AaLS as a novel anti-
gen delivery system for DC-based vaccine development in 
future clinical applications. 
Materials and Methods
Antigenic peptide addition and protein cage purification
The OT-1 (SIINFEKL) and OT-2 (ISQAVHAAHAEINEAGR) 
peptides were added at the N-terminal and the C-terminal 
ends of AaLS subunit, respectively, by an established poly-
merase chain reaction protocol using primers containing spe-
cific enzyme restriction sites and pETDuet based plasmids 
containing genes encoding AaLS protein as a template. The 
amplified DNAs were used to transform the competent Esch-
erichia coli strain BL21 (DE), resulting in the over-expression 
in E. coli of the AaLS protein cages containing added antigen-
ic peptides. The resultant protein was purified as describ ed 
previously [11].
Mass spectrometry 
The subunit masses of AaLS-OT-2, AaLS-OT-1, and wt AaLS 
protein cages were analyzed using an electrospray ionization 
time-of-flight mass (ESI-TOF) mass spectrometer (Xevo G2 
TOF, Waters, Milford, MA, USA) interfaced to a Waters UPLC 
and an autosampler. Samples were loaded onto the MassPREP 
Micro desalting column (Waters) and eluted with a gradient 
of 5-95% (v/v) acetonitrile containing 0.1% formic acid with a 
flow rate of 300 µL/min [11]. Mass spectra were acquired in 
the range of m/z 500-3,000 and processed using MaxEnt 1 
and MaxEnt 3 from MassLynx version 4.1 to obtain the aver-
age mass from multiple charge state distributions.
Mice
C57BL/6 mice were purchased from Taconic, and CD45.2+ 
OT-1 and CD45.2+ OT-2 mice were purchased from the Jack-
son Laboratory. All mice were maintained under specific patho-
gen-free conditions and used at 6-8 weeks with Institutional 
Animal Care and Use Committee guidelines.
Isolation of splenic CD11c+ DCs and ovalbumin-specific T cells
Single cell suspensions of splenocytes were prepared with 
400 U/mL collagenase D (Roche, Basel, Switzerland) and 
CD11c+ cells were positively enriched with magnetic-activat-
ed cell sorting (MACS) sorting (Miltenyl Biotech, Bergisch 
Gladbach ,Germany). Ovalbumin (OVA)-specific CD8+ or 
CD4+ T cells were prepared from OT-1 or OT-2 mice, respec-
tively. Briefly, single cell suspensions from lymph nodes and 
spleens were prepared and CD8+ T cells or CD4+ T cells were 
positively enriched by MACS sorting. Sorted T cells showed 
>98% purity as detected by flow cytometry. All flow cytome-
try data were acquired by BD FACS Calibur and analyzed by 
FlowJo software (TreeStar, San Carlos, CA, USA). 
 
Carboxyfluorescein succinimidyl ester-dilution assay to detect 
antigen-specific T cell proliferation in vitro and in vivo
For in vitro OVA-specific T cell proliferation assay, OT-1 or 
OT-2 T cells were stained with 0.5 μM of carboxyfluorescein 
succinimidyl ester (CFSE) (Invitrogen, Carlsbad, CA, USA) at 
1×107 cells/mL for 10 minutes at 37°C. CD11c+ DCs were pulsed 
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with indicated proteins for 3 hours, washed and then co-cul-
tured with the CFSE-labeled T cells at a ratio of 1:3 (DC, 1×105: 
T cell, 3×105) in a 96-well U-bottom plate at 37°C. After 4 days, 
cells were harvested and then stained for Vβ5.1/5.2 (Bioleg-
end, San Diego, CA, USA), Vα2 and CD8 or CD4 (all from BD, 
San Jose, CA, USA). For in vivo OVA-specific T cell prolifera-
tion assay, naïve C57BL/6 mice were adoptively transferred 
with 5 μM CFSE-labeled OT-1 or OT-2 T cells intravenously at 
day -1. At day 0, mice were injected with indicated proteins in 
the footpads subcutaneously in the presence of 50 μg of poly 
(I:C) (Invivogen, San Diego, CA, USA) as an adjuvant. At day 
3, single cell suspensions were prepared from lymph nodes. 
OVA-specific T cells (Vβ5.1/5.2+Vα2+CD8+ or Vβ5.1/ 5.2+Vα2+CD4+) 
were gated and progressive halving of CFSE fluorescence per 
cell was measured by flow cytometry.
Fig. 2. A schematic diagram showing dendritic cell (DC)-mediated antigen-specific T cell proliferation induced by lumazine synthase protein cage 
nanoparticles (AaLS) carrying OT peptides. 
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Antigen delivery
DC
Processing and presentation
T cell
Antigen-specific  T cell proliferation
Antigen
peptide
DC CD8+  T cell
CD4+  T cell
MHC I
MHC II
Fig. 1. Surface and ribbon diagram representations of AaLS (PDB: 1HQK) looking down the five-fold symmetry axis (A) and clipped view show-
ing the interior space (9 nm interior and 15.4 nm exterior diameters) of the protein cage (B). Five subunits were shown as ribbon diagram with 
individual colors. 
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Results
Surface and ribbon diagram representations of lumazine syn-
thase (AaLS) were depicted (Fig. 1) and a schematic diagram 
showing DC-mediated antigen-specific T cell proliferation 
induced by AaLS carrying OT peptides was shown in Fig. 2. 
 To adapt AaLS protein cage as antigen delivery nanoplat-
forms, we genetically introduced OT-1 (SIINFEKL) and OT-2 
(ISQAVHAAHAEINEAGR) peptides to the N-terminal and 
the C-terminal ends of AaLS subunit, respectively. Antigenic 
peptide insertions were confirmed by DNA sequencing and 
molecular mass measurement of subunits of OT-1 or OT-2 
peptide added AaLS protein cages (AaLS-OT-1 or AaLS-OT-2). 
AaLS-OT-1 and AaLS-OT-2 were individually over-expressed 
in E. coli as a soluble protein without noticeable amounts of 
precipitation. OT-peptide inserted AaLS protein cages were 
purified by the same method used to purify wild-type AaLS 
(wt AaLS), which do not have any OT peptide insertions. ESI-
TOF mass spectrometry analysis indicated that the subunit 
masses of AaLS-OT-2, AaLS-OT-1, and wt AaLS protein cages 
were 18,458.0 Da, 17,576.5 Da, and 16,705.0 Da, respectively, 
which are well matched with their predicted masses (18,458.1 
Da, 17,576.2 Da, and 16,706.3 Da, respectively) (Fig. 3A). Trans-
mission electron microscopic images of stained AaLS-OT-2, 
AaLS-OT-1, and wt AaLS protein cages confirmed an intact 
cage architecture with a uniform size distribution (~16 nm) 
(Fig. 3B). These results indicate that AaLS-OT-2 and AaLS-
OT-1 protein cages form an intact protein cage architecture 
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Fig. 3. Characterization of OT-peptide added AaLS protein cages. (A) Molecular masses of dissociated subunits of AaLS-OT-2 (top), AaLS-OT-1 
(middle), and wt AaLS (bottom) protein cages. Calculated (Calc.) and measured molecular masses were indicated. (B) Transmission electron 
micrographic image of 2% uranyl acetate stained AaLS-OT-2 (top), AaLS-OT-1 (middle), and wt AaLS (bottom) protein cages confirmed an intact 
cage architecture with a uniform size distribution.
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Fig. 4. OT-1 antigenic peptides delivered by AaLS-OT-1 induce OT-1-specific CD8+ T cell proliferation in vitro and in vivo. (A) CD11c+ dendritic 
cells (DCs) were pulsed with phosphate buffered saline (PBS), soluble ovalbumin (OVA) protein, wt AaLS, or AaLS-OT-1 at 2 mg/mL for 3 hours. 
The DCs were washed and then co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-1 T cells at a ratio of 1:3. Four days 
later, the proliferation of OT-1-specific CD8+ T cells was measured by flow cytometry. (B) Mice were adoptively transferred with CFSE-labeled 
OT-1 T cells and on the next day, they were immunized subcutaneously with PBS, 100 μg of OVA protein, 50 μg of wt AaLS, AaLS-OT-1 in the 
presence of an adjuvant. Three days later, the proliferation of OT-1-specific CD8+ T cells was measured by flow cytometry. 
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Fig. 5. OT-2 antigenic peptides delivered by AaLS-OT-2 induce OT-2-specific CD4+ T cell proliferation in vitro and in vivo. (A) CD11c+ dendritic 
cells (DCs) were pulsed with phosphate buffered saline (PBS), soluble ovalbumin (OVA) protein, wt AaLS, or AaLS-OT-2 at 2 mg/mL for 3 hours. 
The DCs were washed and then co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled OT-2 T cells at a ratio of 1:3. Four days 
later, the proliferation of OT-2-specific CD4+ T cells was measured by flow cytometry. (B) Mice were adoptively transferred with CFSE-labeled 
OT-2 T cells and on the next day, they were immunized subcutaneously with PBS, 100 μg of OVA protein, 50 μg of wt AaLS, AaLS-OT-2 in the 
presence of an adjuvant. Three days later, the proliferation of OT-2-specific CD4+ T cells was measured by flow cytometry. 
without significant changes in size and composition.
 To study antigen-specific CD8+ T cell proliferation induced 
by DCs following antigen delivery by AaLS-OT-1 in vitro, DCs 
were pulsed with either wt AaLS or AaLS-OT-1 for three hours 
and were washed to ensure the presentation of only processed 
antigens. DCs pulsed with soluble OVA protein and wt AaLS 
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were used as a positive and a negative control groups, respec-
tively. Each group of DCs were then co-cultured with CFSE-
labeled OT-1 T cells for four days and the proliferation of OT-1 
peptide specific CD8+ T cells were measured by flow cytome-
try. While CFSE fluorescent signals of OT-1 T cells co-cultured 
with DCs pulsed with phosphate buffered saline or wt AaLS 
remain unchanged, those of OT-1 T cells co-cultured with 
DCs pulsed with soluble OVA protein or AaLS-OT-1 appeared 
as a series of peaks with lower CFSE fluorescence intensities 
indicating that OT-1 antigenic peptides delivered to DCs by 
AaLS effectively induced antigen-specific CD8+ T cell prolif-
eration in vitro (Fig. 4A). Antigen-specific T cell proliferation 
induced by AaLS antigen delivery was also confirmed in vivo. 
Naïve mice were adoptively transferred intravenously with 
CFSE-labeled OT-1 T cells and were immunized with AaLS-
OT-1, or with wt AaLS in the presence of poly (I:C) as an ad-
juvant. Soluble OVA protein (100 μg per mouse) was also used 
as a positive control in parallel. Similar to OT-1 peptide spe-
cific T cell proliferation data in vitro, CFSE signals of OT-1 T 
cells from mice immunized either with soluble OVA protein 
(a positive control) or AaLS-OT-1 showed serially diluted peaks 
with decreasing CFSE fluorescence intensity, sug gesting that 
OT-1 antigenic peptides delivered to DCs by AaLS effectively 
induced antigen-specific CD8+ T cell proliferations in vivo as 
well (Fig. 4B). 
 Similar approaches were applied to examine antigen-spe-
cific CD4+ T cell proliferation following antigen delivery via 
AaLS-OT-2 in vitro and in vivo. The data showed that only 
those of T cells co-cultured with DCs pulsed with soluble 
OVA protein (a positive control) or AaLS-OT-2 proliferated, 
showing that OT-2 antigenic peptides delivered to DCs by 
AaLS effectively induce antigen-specific CD4+ T cell prolifera-
tion in vitro (Fig. 5A). CFSE-labeled OT-2 T cells were adop-
tively transferred and proliferated when immunized either 
with soluble OVA protein or AaLS-OT-2, demonstrating that 
AaLS deliver OT-2 antigenic peptides to DCs efficiently in vi-
vo as well (Fig. 5B). Taken together, these data demonstrate 
that antigenic peptides carried by AaLSs are successfully de-
livered, processed, and presented by DCs leading to antigen-
specific T cell proliferation, which demonstrated the value of 
AaLS as a novel antigen delivery system. 
Discussion
In this study, we propose a lumazine synthase protein cage as 
an efficient antigen delivery system to DCs and a potential 
candidate for a new DC-based vaccine carrier in the future. 
In comparison to other nano-sized materials such as poly-
mers, inorganic nanoparticles, liposomes, and/or VLP, pro-
tein cage nanoparticles have the virtue of simplicity and re-
producibility; protein cages are modified and produced by 
genetic engineering and thus, not only the ratios of antigen to 
carrier can be controlled consistently but also the original 
structure and functions of inserted antigens, which are main-
ly proteins, can be maintained intact. Besides, protein cages 
are biocompatible and degrade safely demonstrating high 
practical feature in future various clinical applications. 
 Antigenic peptide insertion did not cause any significant 
conformational changes in AaLS. Moreover, such inserted 
antigenic peptides into AaLS were functional so that DCs could 
process and present them leading to the induction of antigen-
specific T cell proliferation. The efficacy of antigen delivery to 
DCs via AaLSs was comparable to a conventional way of puls-
ing with soluble proteins to DCs, based on our data showing 
similar level of T cell proliferative responses between 100 μg 
of soluble OVA protein and 50 μg of AaLS-OTs per mouse 
(AaLS-OT-1 or AaLS-OT-2) where the contained amounts of 
OT-peptide epitopes were similar to each other. Further dos-
age experiments are necessary to examine the efficacy of an-
tigen delivery via AaLSs. 
 To improve the efficacy as well as the specificity of antigen-
delivery to DCs has been one of the main subjects for optimal 
DC-based vaccine development. Among various approaches, 
DC-targeting strategy might be the latest technology, which 
is composed of a fusion antibody against DC-specific antigen 
uptake receptors of which heavy chains are conjugated with 
an antigen of interest and a systemic administration of adju-
vants for proper DC maturation [15]. To date, the concept of 
DC-targeting strategy and efficacy as a DC-based vaccine has 
been validated in various disease models [16-18]. Nonethe-
less, still following aspects of the DC-targeting strategy are 
needed to be considered for improved future clinical applica-
tions; limitations of size and solubility of the conjugated anti-
gens to the DC-targeting antibodies [19], low cost effective 
strategy due to the requirement of mammalian cell transfec-
tion for functional antibody production [20], and any adverse 
hyperactivations caused by a systemic administration of ad-
juvants [21,22]. Exploring nanotechnology of protein cage 
might provide useful solutions for these challenges and could 
advance the DC-based vaccine development since protein 
cage nanoplatforms feature with broader choices of size and 
solubility of antigens, more cost effective due to production 
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in E. coli, as well as with co-insertion of selective adjuvants 
and antigens together. Furthermore, various protein cages 
containing selective antigens and adjuvants can be mixed 
and matched with known DC-targeting antibodies, and such 
interdisciplinary synergy will open a new avenue of DC-based 
vaccine design and development.
 In conclusion, this study sets the stage for the analysis of 
functional roles of lumazine synthase protein cages as effi-
cient DC-based vaccine carrier in various disease models. 
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